Faculty Collaboration Database

1. Kruskall MS, Bodner MS, Dzik WH, Friedman KD, Gerber L, Gould SA, Gravlee G, Schoenleber DG, Yomtovian R. An annotated bibliography on autologous transfusion. Transfusion. 1992;32(3):286-90.

2. Kroner PA, Friedman KD, Fahs SA, Scott JP, Montgomery RR. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease. J Biol Chem. 1991 Oct 15;266(29):19146-9.

3. Friedman KD, Rosen NL, Newman PJ, Montgomery RR. Enzymatic amplification of specific cDNA inserts from lambda gt11 libraries. Nucleic Acids Res. 1988 Sep 12;16(17):8718. PMCID: PMC338596

4. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988 Aug;72(2):616-20.

5. Tollefson DF, Friedman KD, Marlar RA, Bandyk DF, Towne JB. Protein C deficiency. A cause of unusual or unexplained thrombosis. Arch Surg. 1988 Jul;123(7):881-4.

6. Friedman KD, Borok Z, Owen J. Heparin cofactor activity and antithrombin III antigen levels in preeclampsia. Thromb Res. 1986 Aug 15;43(4):409-16.

7. Goodnough LT, Price TH, Parvin CA, Friedman KD, Vogler WR, Khan N, Sacher R, Johnston M, Wissel M, Ciavarella D. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol. 1994 Aug;87(4):695-9.

8. Kruskall MS, Yomtovian R, Dzik WH, Friedman KD, Umlas J. On improving the cost-effectiveness of autologous blood transfusion practices. Transfusion. 1994 Mar;34(3):259-64.

9. Goodnough LT, Price TH, Friedman KD, Johnston M, Ciavarella D, Khan N, Sacher R, Vogler WR, Wissel M, Abels RI. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion. 1994 Jan;34(1):66-71.

10. Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR. Critical von Willebrand factor A1 domain residues influence type VI collagen binding. J Thromb Haemost. 2012 Jul;10(7):1417-24. PMCID: PMC3809952

11. Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Clin Cancer Res. 1995 Oct;1(10):1145-52.

12. Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease. J Thromb Haemost. 2012 Jul;10(7):1425-32. PMCID: PMC3809762

13. Hessner MJ, Luhm RA, Pearson SL, Endean DJ, Friedman KD, Montgomery RR. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost. 1999 May;81(5):733-8.

14. Foucar K, Friedman K, Llewellyn A, McConnell T, Aisenbrey G, Argubright K, Ballinger L. Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down's syndrome. Am J Clin Pathol. 1992 Apr;97(4):584-90.

15. Kruskall MS, Bodner MS, Dzik WH, Friedman KD, Gerber L, Gould SA, Gravlee G, Schoenleber DG, Yomtovian R. An annotated bibliography on autologous transfusion. Transfusion. 1992;32(3):286-90.

16. Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2013 May;53(5):972-80.

17. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers. Br J Haematol. 1999 Jul;106(1):237-9.

18. Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH. Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatr Blood Cancer. 2013 Mar;60(3):500-2. PMCID: PMC4461026

19. Dinauer DM, Friedman KD, Hessner MJ. Allelic distribution of the glycoprotein Ia (alpha2-integrin) C807T/G873A dimorphisms among caucasian venous thrombosis patients and six racial groups. Br J Haematol. 1999 Dec;107(3):563-5.

20. Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Hoffmann RG, Montgomery RR, Haberichter SL, Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem. 2013 Apr;59(4):684-91. PMCID: PMC3852672

21. Hessner MJ, Budish MA, Friedman KD. Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes. Clin Chem. 2000 Aug;46(8 Pt 1):1051-6.

22. Ledford M, Friedman KD, Hessner MJ, Moehlenkamp C, Williams TM, Larson RS. A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay. J Mol Diagn. 2000 May;2(2):97-104. PMCID: PMC1906901

23. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood. 2013 May 02;121(18):3742-4. PMCID: PMC3643771

24. Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013 Aug;11(8):1511-8. PMCID: PMC3807872

25. Hessner MJ, Friedman KD, Voelkerding KV, Huber S, Ryan D, Nuccie B, Ledford M. Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assay. Clin Chem. 2001 Nov;47(11):2048-50.

26. Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014 Jun;111(6):1133-40.

27. Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004 Sep 01;104(5):1350-5.

28. Francis JC, Hui SK, Mahoney D Jr, Dietrich JE, Friedman KD, Soundar E, Srivaths LV. Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H. Haemophilia. 2014 May;20(3):e211-4.

29. Raife T, Friedman KD, Fenwick B. Lepirudin prevents lethal effects of Shiga toxin in a canine model. Thromb Haemost. 2004 Aug;92(2):387-93.

30. Allan JN, Friedman KD, DeSancho MT. Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N. Int J Hematol. 2014 Dec;100(6):602-6.

31. Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost. 2004 Sep;2(9):1601-9.

32. Cooley BC, Chen CY, Friedman KD, Datta Y. A prothrombotic phenotype in the Copenhagen rat strain. Thromb Res. 2005;115(1-2):153-7.

33. Costello JP, Diab YA, Philippe-Auguste M, Jones MB, Shankar V, Friedman KD, Nath DS. Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review. World J Pediatr Congenit Heart Surg. 2014 Oct;5(4):592-8.

34. Gosselin RC, Adcock Funk DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, Moll S. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban. Arch Pathol Lab Med. 2014 Dec;138(12):1680-4.

35. Kakela JK, Friedman KD, Haberichter SL, Buchholz NP, Christopherson PA, Kroner PA, Gill JC, Montgomery RR, Bellissimo DB. Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis. Mol Genet Metab. 2006 Mar;87(3):262-71.

36. Raife TJ, Friedman KD, Dwyre DM. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion. 2006 Jan;46(1):74-9.

37. Muia J, Zhu J, Gupta G, Haberichter SL, Friedman KD, Feys HB, Deforche L, Vanhoorelbeke K, Westfield LA, Roth R, Tolia NH, Heuser JE, Sadler JE. Allosteric activation of ADAMTS13 by von Willebrand factor. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18584-9. PMCID: PMC4284596

38. Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR, Zimmerman Program Investigators. Crucial role for the VWF A1 domain in binding to type IV collagen. Blood. 2015 Apr 02;125(14):2297-304. PMCID: PMC4383803

39. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006 May;4(5):967-70.

40. Hillarp A, Friedman KD, Adcock-Funk D, Tiefenbacher S, Nichols WL, Chen D, Stadler M, Schwartz BA. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method. Haemophilia. 2015 Nov;21(6):837-45.

41. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion. 2007 Jan;47(1):120-5.

42. Slayton WB, Patel M, Sola-Visner M, Harris N, Rivers A, Montgomery RR, Friedman KD. Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow. J Pediatr Hematol Oncol. 2008 Sep;30(9):708-11. PMCID: PMC5592795

43. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016 Feb;14(2):248-61.

44. Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D, Young G, Luddington RJ. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. J Thromb Haemost. 2016 Apr;14(4):757-64.

45. Dwyre DM, Dursteler B, Nashelsky M, Friedman KD, Raife TJ. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura. J Clin Apher. 2009;24(3):106-10.

46. Erickson YO, Samia NI, Bedell B, Friedman KD, Atkinson BS, Raife TJ. Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher. 2009;24(4):150-4. PMCID: PMC2750870

47. Epperla N, Hemauer K, Friedman KD, George JN, Foy P. Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol. 2016 Jun;91(6):644-6.

48. Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR. Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function. J Thromb Haemost. 2009 Nov;7(11):1832-9. PMCID: PMC3825106

49. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016 May 19;127(20):2481-8. PMCID: PMC4874228

50. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010 Jul 15;116(2):280-6. PMCID: PMC2910611

51. Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P. Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol. 2016 Jun;91(6):E313-4.

52. Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR. Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD. J Thromb Haemost. 2010 Jun;8(6):1431-3. PMCID: PMC3892206

53. Abbott DW, Friedman KD, Karafin MS. Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findings. Transfus Apher Sci. 2016 Dec;55(3):318-322.

54. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H, International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017 Feb;15(2):312-322.

55. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR. Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood. 2011 Feb 10;117(6):e67-74. PMCID: PMC3056647

56. Bercovitz RS, Drew CS, Bushee CL, Popovsky MA, Friedman KD, Anani WQ. A microfluidic analysis of thrombus formation in reconstituted whole blood samples comparing spray-dried plasma versus fresh frozen plasma. Vox Sang. 2021 May;116(5):540-546.

57. Gupta M, Lillicrap D, Stain AM, Friedman KD, Carcao MD. Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease. Pediatr Blood Cancer. 2011 Dec 01;57(6):1081-3.

58. MacQuarrie KL, Williams O, Friedman KD, Bercovitz RS. Compound heterozygous protein C variants undetectable by common laboratory testing causing purpura fulminans after the neonatal period. Am J Hematol. 2020 Dec;95(12):1616-1621.

59. Samia NI, Friedman KD, Gottschall JL, Raife TJ. Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy. J Clin Apher. 2011;26(3):138-45.

60. Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost. 2011 Jul;37(5):528-34. PMCID: PMC3807766

61. van Dorland HA, Taleghani MM, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, Vesely SK, Matsumoto M, Lämmle B, Fujimura Y, Kremer Hovinga JA, Hereditary TTP Registry. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019 Oct;104(10):2107-2115. PMCID: PMC6886414

62. Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood. 2012 Mar 01;119(9):2135-40. PMCID: PMC3311248

63. Horn C, Négrier C, Kalina U, Seifert W, Friedman KD. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays. J Thromb Haemost. 2019 Jan;17(1):138-148. PMCID: PMC7379984

64. Cushing M, Kawaguchi K, Friedman KD, Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012 Jul;52(7):1535-41.

65. Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL. Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood. 2012 May 10;119(19):4543-53. PMCID: PMC3362367

66. St Ledger K, Feussner A, Kalina U, Horn C, Metzner HJ, Bensen-Kennedy D, Blackman N, Veldman A, Stowers A, Friedman KD. International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories. J Thromb Haemost. 2018 Mar;16(3):555-564.

67. Fattah H, Kumar D, George JN, Massey HD, King AL, Friedman KD, Gupta G. Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). Transfusion. 2017 Dec;57(12):3058-3062.

68. Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB. Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy. Transfusion. 2017 Nov;57(11):2775-2781.

69. Tarasco E, Bütikofer L, Friedman KD, George JN, Hrachovinova I, Knöbl PN, Matsumoto M, von Krogh AS, Aebi-Huber I, Cermakova Z, Górska-Kosicka M, Jalowiec KA, Largiadèr CR, Prohászka Z, Sinkovits G, Windyga J, Lämmle B, Kremer Hovinga JA. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021 Jun 24;137(25):3563-3575.

70. Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lämmle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021 Apr 08;137(14):1855-1861.

71. Wang R, Furihata K, McFarland JG, Friedman K, Aster RH, Newman PJ. An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest. 1992 Nov;90(5):2038-43. PMCID: PMC443268

72. Liebmann J, Friedman K. Adynamic ileus in a patient with non-small-cell lung cancer after treatment with vinorelbine. Am J Med. 1996 Dec;101(6):658-9.

73. Pamidi S, Friedman K, Kampalath B, Eshoa C, Hariharan S. Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients. Transplantation. 2000 Jun 27;69(12):2666-9.

74. Goddet B. [A center for the prevention and detection of sexually transmitted diseases. The nurse's role]. Soins Gynecol Obstet Pueric Pediatr. 1992 Nov(138):45-8.

75. Rawal A, Sarode R, Curtis BR, Karandikar NJ, Friedman K, Rogers ZR. Acquired Glanzmann's thrombasthenia as part of multiple-autoantibody syndrome in a pediatric heart transplant patient. J Pediatr. 2004 May;144(5):672-4.

76. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD. Comparison and stability of ADAMTS13 activity in therapeutic plasma products. Transfusion. 2007 Jan;47(1):120-5.

77. McAteer MJ, Dumont LJ, Cancelas J, Rugg N, Vassallo R, Whitley P, Graminske S, Friedman K. Multi-institutional randomized control study of haemolysis in stored red cell units prepared manually or by an automated system. Vox Sang. 2010 Jul 01;99(1):34-43.

78. Lee CA, Hubbard A, Sabin CA, Budde U, Castaman G, Favaloro EJ, Friedman KD, Federici AB, I5th-SSC Subcommittee on VWF. Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas. J Thromb Haemost. 2011 Jan;9(1):220-2.

79. Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost. 2011 Jul;37(5):528-34. PMCID: PMC3807766

80. Annen K, Friedman K, Eshoa C, Horowitz M, Gottschall J, Straus T. Two cases of transfusion-transmitted Anaplasma phagocytophilum. Am J Clin Pathol. 2012 Apr;137(4):562-5.

81. Flood VH, Johnsen JM, Kochelek C, Slobodianuk TL, Christopherson PA, Haberichter SL, Udani R, Bellissimo DB, Friedman KD, Montgomery RR. Common <i>VWF</i> sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD. Res Pract Thromb Haemost. 2018 Apr;2(2):390-398. PMCID: PMC5974909

82. Irani MS, Sanchez F, Friedman K. Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma. Transfusion. 2020 Aug;60(8):1666-1668.

83. Bercovitz RS, Drew CS, Bushee CL, Popovsky MA, Friedman KD, Anani WQ. A microfluidic analysis of thrombus formation in reconstituted whole blood samples comparing spray-dried plasma versus fresh frozen plasma. Vox Sang. 2021 May;116(5):540-546.

84. Tarasco E, von Krogh AS, Hrdlickova R, Braschler TR, Iwaniec T, Knöbl PN, Hamada E, Pikovsky O, Farese S, Gutwein O, Kessler P, Schultz NH, von Auer C, Windyga J, Friedman K, Hrachovinova I, George JN, Matsumoto M, Schneppenheim R, Lämmle B, Kremer Hovinga JA. Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. Res Pract Thromb Haemost. 2022 Oct;6(7):e12814. PMCID: PMC9585384

85. Tarantino MD, Hardesty B, Metjian A, Ortel TL, Chen J, Badejo K, Ma A, Cuker A, Rajasekhar A, Friedman KD, Janbain M. Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study. Haemophilia. 2023 Sep;29(5):1259-1268.

86. Kozak M, Rubenstein W, Okwan-Duodu D, Friedman K, Nassir Y, Perez-Alvarez I, Gibb DR, Klapper E, Pepkowitz S. Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy. Transfusion. 2023 Jun;63(6):1241-1245.

87. Foy P, Friedman KD, Michaelis LC. How I diagnose and treat thrombocytopenia in geriatric patients. Blood. 2024 Jan 18;143(3):214-223.

88. Jackson UC, Fox HE, Owen J, Friedman KD. Administration of antithrombin III in the management of severe preeclampsia: A pilot study. J Maternal Fetal Med 1992; 308-312.

89. Friedman, KD. Management of clotting disorder/deep vein thrombosis in the dying patient. Principles and Practice of Supportive Oncology 2001;4:1-16.

90. Kessler CM, Friedman KD, Schwartz BA, Gill JC, Powell JS, and the Wilate® PK study investigators: The pharmacokinetic characteristics of two VWF/FVIII concentrates in subjects with congenital von Willebrand disease: Results from a prospective randomized crossover study. Thrombosis and Haemostasis, 2011:106:279-288.

91. Astermark H, Friedman, KD, Adcock-Funk D, Tiefenbacher S, Nichols WL, Chen D, Stadler M, Schwartz BA. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method. In press pending comments Haemophilia 2014

92. Ragni MV, Callis,J, Dauod N, Hu B, Kouides P, Santos J, Schwartz J, Friedman K, Kuriakose P, Leavitt A, Lim M, Machin N, Recht M, Chrisentery-Singleton T. Observational Cohort Study of Long-Term Outcomes of Liver Transplantation in Hemophilia Accepted for publication, Haemophilia HAE-00317-2023.R1

1. Friedman KD, Rosen NL, Newman PJ, Montgomery RR. Screening of lambda gt111 libraries. In: Innis M, Gelland D, Sninsky J, White T, eds. PCR Protocols: A Guide to Methods and Applications. Orlando: Academic Press, 1990:253 258.

2. Stehling LC, Dzik WH, Friedman KD, Gerber L, Gould S, Kleinman S, Kruskall M, Popovsky MA, Schoenleber DG, Yomtovian R. Guidelines for blood salvage and reinfusion in surgery and trauma. Arlington, VA: American Association of Blood Banks, 1990.

3. Friedman KD (moderator): Autologous transfusion programs: Discussion 1 in Stehling LC (Editor): Perioperative Autologous Transfusion. Arlington, VA: American Association of Blood Banks, 1991:57 66.

4. Friedman KD, Menitove JE: Preparation and clinical use of plasma and plasma fractions. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ. Williams Hematology. New York 2000

5. Friedman, KD, Raife TJ. Management of clotting disorder/deep vein thrombosis in the dying patient. In: Berger AM, Portenoy RK, Weissman DE, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins 2002;452-462.

6. Raife TJ, Friedman, KD. Therapeutic use of Blood Components. In: Rakel RE Bope ET, eds. Conn’s Current Concepts 2002 Philadelphia: WB Saunders Company 2002;450-460.

7. Friedman KD, Rodgers GM: Inherited coagulation disorders. In: Lee RG, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe’s Clinical Hematology Baltimore: Williams and Wilkins, 2003.

8. Friedman, KD, Raife TJ. Management of hypercoagulable states and coagulopathy. In: Berger AM, Portenoy RK, Weissman DE, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins; 2006; 347-355. 2007.

9. Friedman, KD. Hemostatic Disorders. In King KE, Bandarenko N, Campbell-Lee SA, Cooling LW, Cushing MM, Friedman KD, Pomper G, Gottschall JL, eds. Blood Transfusion Therapy: A Physician’s Handbook. Bethesda MD. AABB 2011; 101-144.

10. Petkova JH, Raife TJ, Friedman, KD. Management of hypercoagulable states and coagulopathy. In: Berger AM, Shuster JL, Van Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology Philadelphia: Lippincott Williams & Wilkins 2013;430-441.

11. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988 Aug;72(2):616-20.

12. Friedman KD, Petkova Prolonged PTT. In. Licthin A and Bartholomew J ed. The Coagulation Consultant: A practical Guide Philadelphia: Springer Science+Business Media, New York NY 2013;pp 430-441.

13. Petkova, JH, Friedman KD: Other Congenital Coagulopathies. In McQueen CA, eds. Reference Module in Biologic Sciences. Elsevier Ltd. Oxford UK. 2014; https://doi.org/10.1016/B978-0-12-801238-3.00067-2.

14. Rose WN, Friedman KD, Raife TJ. The role of thrombin in hemolytic uremic syndrome and other thrombotic microangiopathies. In Clayton G, ed. Hemolytic Uremic Syndrome: Symptoms, Therapy and Prognosis. Nova-Science. Hauppauge NY. 2014.

15. Schneidewend, R, Epperla N, Friedman KD, Thrombotic thrombocytopenic purpura and the hemolytic uremic syndromes. In Hoffman R, Benz EJ, Silverstein LE, Heslop H, Weitz J, Anastasi J. Hematology, Basic Principles and Practice. 7th Ed. Elsevier Ltd. Philadelphia PA. 2017; pp 1084-2000.

16. Friedman, KD. Hemostatic Disorders. In, Cushing L, Poisson M, Bandarenko N, eds. Blood Transfusion Therapy: A Physician’s Handbook. 13th edition. Bethesda MD. AABB 2020, pp 91-156.

17. Smock KJ, Friedman KD. Laboratory hematology. In American Society of Hematology Self Assessment Program. 8th Edition, Washington DC. American Society of Hematology. 2021.

18. George GE, Friedman KD, Thrombotic thrombocytopenic purpura and the hemolytic uremic syndromes. In Hoffman R, Benz EJ, Silverstein LE, Heslop H, Weitz JI, Salama ME, Abutalib SA. Hematology, Basic Principles and Practice. 8th Ed. Elsevier Ltd. Philadelphia PA. 2023; pp 2063-2080.

19. Muller SB, Friedman KD, Principles of laboratory tests for VWF and coagulation factor function and disorders. In Abutalib S, Connors JM, Ragni MV. Non-malignant hematology – Expert clinical review: Questions and Answers. 2nd Edition. Cham, Switzerland. (manuscript submitted)

1. Friedman KD, Powell JS, Bensen-Kennedy D. Response: The coagulation laboratory monitoring of AFSTYLA single-chain FVIII concentrate. Haemophilia. 2018 May;24(3):e129-e131.

2. George G, Friedman KD, Curtis BR, Lind SE. Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination. Am J Hematol. 2021 Aug 01;96(8):E301-E303.

1. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator. J Clin Invest. 1987 Jun;79(6):1642-7. PMCID: PMC424490

2. Flood VH, Johnsen JM, Kochelek C, Slobodianuk TL, Christopherson PA, Haberichter SL, Udani R, Bellissimo DB, Friedman KD, Montgomery RR. Common <i>VWF</i> sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD. Res Pract Thromb Haemost. 2018 Apr;2(2):390-398. PMCID: PMC5974909

3. Friedman KD, Borok Z, Owen J. Heparin cofactor and antithrombin III levels in pre-eclampsia. Thrombosis and Haemostasis 1985;54(1):254.

4. Green NS, Friedman KD, Owen J. Fibrinogen related antigen in the capillary blood of newborns. Thrombosis and Haemostasis 1985;54(1):255.

5. Owen J, Friedman KD, Grossman BA, Wilkens C, Berke AD, Powers ER. Fibrino-genolysis induced by tissue plasminogen activator and by streptokinase. Blood 1985; 66(5):325a.

6. Owen J, Friedman KD, Grossman BA, Wilkens C. Berke AD, Powers ER. Intra¬venous infusion of streptokinase or tissue plasminogen activator induces fibrin I formation. Blood 1985;66(5):325a.

7. Owen J, Friedman KD, Grossman BA, Wilkens C, Berke AD, Powers ER. Transient activation of coagulation system in response to infusion of streptokinase or of tissue plasminogen activator. Clinical Research 1986;34:332a.

8. Friedman KD, Marlar RA, Gill JC, Endres Brooks J, Montgomery RR: Protein S deficiency in patients with the lupus inhibitor. Blood 1986;68:322a.

9. Friedman KD, Marlar RA, Houston JG, Montgomery RR: Warfarin induced skin necrosis in a patient with protein S deficiency. Blood 1986;68:323a.

10. Montgomery RR, Vokac EA, Scott JP, Reynolds ER, Rosen NL, Newman PJ, Friedman KD. Does von Willebrand factor bind to endothelial cells through a GPIb like receptor? Blood 1988;72:333a.

11. Benziger J, Singaraju C, Friedman KD. Do newborns tolerate the potassium load of stored irradiated blood cell transfusion? Transfusion 1990;30:117a.

12. Friedman KD, Fox L, Clark DA. Plasma factors in a patient with cancer related hemolytic uremic syndrome. Clinical Research 1991;39.

13. Kroner FA, Friedman KD, Fahs S, Vokac E, Montgomery RR. Molecular abnor¬mal¬ity of the factor VIII binding region of von Willebrand factor. Pediatric Research 1991.

14. Friedman KD, McDonough WC, Cimino DF. The effect of prestorage irradiation on post transfusion red blood cell recovery. Transfusion 1991;31:508.

15. Kroner FA, Fahs SA, Vokac EA, Friedman KD, Montgomery RR. Novel missense mutation in von Willebrand factor associated with defective vWf/factor VIII inter¬ac¬tion in a patient with type 1 von Willebrand disease. Blood 1991;78:178a.

16. Wang RG, McFarland J, Furihata K, Friedman KD, Newman FJ. An amino acid poly-morphism with the PENA/PENB alloantigen system. Blood 1991;78:281a.

17. Whitehead RF, Friedman KD, Clark DA. A phase 1 trial of subcutaneous interleukin 2 and interleukin 4. Proceedings AACR 1992;33:231.

18. Friedman KD, Backstrom C, Armon M. Newborn tolerance of potassium load from simple transfusion of stored irradiated red blood cells. Transfusion 1992;32:10s.

19. Whitehead RF, Friedman KD, Clark DA, Padilla SR. A phase 1 trial of subcutaneous interferon 1α. Proceedings AACR 1993;34:464.

20. Rock AL, Kroner PA, Fahs S, Kluessendorf M, Friedman KD, Montgomery RR. Interaction of von Willebrand factor (vWf) mutations on GPIb and F VIII binding variants of von Willebrand disease (vWf). Blood 1993;82:330a.

21. Friedman KD, Gribble TJ. Genetic basis for type IIB von Willebrand disease in New Mexican patients. Transfusion 1994.

22. Gribble TJ, Friedman KD, Smith KJ, Herrera RF. A low level non responding factor VIII inhibitor precedes a high titer responding inhibitor. Proceedings of the 21st International Congress of the World Federation of Hemophilia, Mexico City 1994

23. Hart AP, Malhotra D, Friedman KD, Dasgupta A. Improved lipid profiles in hemo-dialysis patients with dialyzer blood flow rate of 400 ml/min or higher. Presented at Academy of Clinical Laboratory Physicians and Scientist, 1995.

24. Friedman KD, Sierra E, McDonough W, Nelson EJ, Mouradkhanian, MJ. Evaluation of the Leukotrap WB CFDA 1 system for production of Leukocyte reduced red cells from 500 milliliter cells. Transfusion 1996;36:9S.

25. Friedman KD, Sierra E, McDonough W, Nelson EJ, Mouradkhanian MJ. Evaluation of the Leukotrap RC FL System for production of Leukocyte reduced platelet con¬cen¬trate from 500 milliliter collections. Transfusion 1996;36:13S.

26. King LC, Lowery MC, Sciotto CG, Viswanatha D, Friedman KD, McConnell T. Flow cytometric and cytogenetic abnormalities in four patients with minimally differ¬entiated acute non lymphocytic leukemia. Applied Cytogenetics 1996;22:98.

27. Yoshida T, Lee J, McDonough W, Friedman K, Bitenski M. Anaerobic refrigerated storage of red blood cells for nine weeks: In vivo and in vitro characteristics. Transfusion 1997;37:104S.

28. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Evaluation of the glycoprotein 1A (GP1a) 807TT, the methylene tetrahydrofolate reductase (MTHFR) 677TT, and the prothrombin 20210GA genotypes as cooperative risk factors for venous thrombosis among Factor V 1691GA (Leiden) carriers. Blood 1998;92:304a.

29. Hessner MJ, Dinauer DM, Luhm RA, Endean DJ, Raife TJ, Friedman KD, Kunicki TJ. Glycoprotein Ia (α2-integrin) C807T allelic distribution among venous thrombo¬sis patients, thrombotic thrombocytopenic purpura (TTP) patients, and six racial groups. Blood 1998;92:190a.

30. Friedman KD, Endres JL, McGaffey KM. Characterization of coagulation factor concentrations in solvent/detergent treated pooled plasma (Plas+SD) and single donor fresh frozen plasma. Thromb Haemostas 1999;82 supp:564.

31. Abu-Hajir M, Kuhlmann RS, Wigton TR, Friedman KD. Low-molecular weight heparin (LMWH) in pregnancy: Role of anti-Xa monitoring. Thromb Haemostas 1999;82 suppl:846.

32. Raife TJ, Atkinson BS, Montgomery RR, Friedman KD. Von Willebrand factor proteolytic activity: correlation with clinical parameters in 94 adult thrombotic thrombocytopenic purpura/hemolytic uremic syndrome patients. Blood 1999;94:16a.

33. Abu-Hajir M. Kuhlmann RS, Wigton TR, Friedman KD. Enoxaparin full-dose anticoagulation in pregnancy adjusted for blood levels rather than body weight. Blood 1999;94:28a.

34. Hessner MJ, Dinaur DM, Luhm RA, Endean DJ, Friedman KD, Raife TJ. Allelic distribution of vascular disease-associated genetic risk factors among healthy donors as a function of age. Blood 1999;94:240a.

35. Montgomery RR, Jozwiak MA, Hutter JJ, Endres JL, Foster PA, Friedman KD. A homozygous variant of von Willebrand factor (vWF) that fails to C-terminal dimerize resulting in loss of vWF multimers larger than dimer. Blood 1999;94:443a.

36. Friedman KD, Luhm RA, Scott JP. Maloney KW, Wetzel N, Endres J, Montgomery RR. Factitious diagnosis of von Willebrand disease (VWD) with a mutation in von Willebrand Factor (VWF) that affects the ristocetin cofactor assay but does not significantly affect VWF function in vivo. Blood 2001; 98: 536a.

37. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel N, Jozwiak M, Habericter SL, Christopherson P, Montgomery RR. A mutation in the D4 domain of von Willebrand factor (VWF) results in a variant of type 1 von Wilebrand disease with accelarated in-vivo VWF clearance. Blood 2002;100:128a.

38. Friedman KD, Ottum MD, Endres JL, Montgomery RR, Gill JC. Unexpected breakthrough bleeds in hemophilic children on treatment with B-domain-deleted factor VIII concentrate (Bdd-F8): Studies of factor VIII:c recovery and half-life in 3 symptomatic children. Blood 2002;100:129a.

39. Talano J-AM, Johnson ST, Friedman KD, Ilstrup SJ, Curtis BR, Scott JP, Gottschall JL: Serologic characteristics of three cases of IgA mediated autoimmune hemolytic anemia (AIHA) confirmed by flow cytometry. Blood 2002;100:283a.

40. Boylan B, Rathore V, Paddock C, Friedman K, Curtis B, Stapleton M, Newman DK, Chen H, Kahn M, Newman PJ. JAQ-2/3-like ITP—A newly recognized clinical syndrome caused by autoantibody-mediated clearance of the GPVI/FcRδ-chain complex from the human platelet surface. Blood 2003;102:12a.

41. Kroner P, Gill J, Haberichter S, Bellissimo D, Friedman K, Buchholz N, Desai D, Montgomery R. Type 2M von Willebrand disease caused by a novel Q1402P sub¬stitution in the Botrocetin binding site of the von Willebrand factor A1 domain. Blood 2003: 102:___a.

42. Kakela J, Friedman K, Wetzel N, Kroner P, Gill J , Montgomery R, Bellissimo D. Genetic Mutations in von Willebrand Disease Identified By DHPLC and DNA Sequence Analysis. Blood 2003; 102:90a

43. Gavazova S, Gill JC, Scott JP, Hillery CA, Friedman KD, Wetzel NP, Haberichter SL, Montgomery RR. Assay of the von Willebrand factor propeptide in patients with Type 1 von Willebrand disease (VWD) and the identification of patients with a S2179F mutation in the D4 region of von Willebrand factor. J Thromb Haemost 2003;1 (suppl 1):OC276.

44. Friedman KD, Gruppo RA, Ebert DD, Kakela JK, Bellissimo DB, Endres JL, Wetzel N, Montgomery RR. A case of compound Type 2N/Type 1 von Willebrand disease linked to a novel von Willebrand factor exon 18 mutation A2311G encoding for Met 771 val. J Thromb Haemost 2003; 1 (suppl 1):PO100.

45. Kroner PA, Friedman KD, Valentino LA, Chazek EE, Wetzel N, Benziger LB, Montgomery RR. 2M von Willebrand disease due to linked P1266Q and V1279I substitutions in the von Willebrand factor A1 domain. J Thromb Haemost 2003:1 (suppl 1):OC351.

46. Komwilaisak, P, Price V, Stain AM, Lillicrap D, Blanchette VS, Carcao M: Mild Hemophilia A vs VWD type 2N (Normandy): Confusion in the diagnosis may lead to treatment failure. Presented at World Federation of Hemophilia, Thailand 2004.

47. Lankiewicz MW, Hays J, Friedman KD, Blatt PM: Urgent reversal of warfarin anticoagulation with prothrombin complex concentrate. Blood 2004;104:744a.

48. Komvilaisik P, Stain AM, Lillicrap D, Friedman K, Blanchette V, Carcao M, Price V: Mild haemophilia vs. von Willebrand disease type 2N: confusion in the diagnosis may lead to treatment failure. Haemophilia 2004:10:140.

49. Scott EA, Puca KE, Pietz BC, DuChateau BK, Friedman KD: Analysis of ADAMTS13 activity in plasma products using a modified FRETS-VWF73 assay. Blood 2005;106:165a.

50. Scott EA, Puca KE, Heraly J, Friedman KD, Gottschall JL: Coagulation factor activity and stability in thawed 24-hour plasma stored for 5 days. Submitted to Transfusion 2007;47:33A.

51. Friedman KD, Raife TJ, Endres JL, Pietz BC: Correlations between ADAMTS13 activity and inhibitor levels: Observations and implications for resource utilization. J Thromb Haemost 2007; 5 Suppl 2:P-M-291.

52. Lee CA, Hubbard A, Sabin CA, Budde U, Castaman G, Favaloro EJ, Friedman KD, Mazurier C, Srivastava A, Weinstein M, Montgomery RR, Lillicrap D, Federici AB: Report of eh SC-VWF Working Party on VWF assays in VWD diagnosis. J Thromb Haemost 2007; 5 Supplement 2: P-W-164.

53. Montgomery RR, Morateck P, Christopherson PA, Kautza BC, Miller CA, Branchford BR, Flood VH, Haberichter SL, Bellissimo DB, Friedman KD, Kenny DJ, and Gill JC Functional Assay of VWF Measured by Its Interaction with Platelet GPIb without the Use of Ristocetin. Blood 2007; 110:3158.

54. Bellissimo DB, Christopherson PA, Haberichter SL, Flood VH, Gill JC , Friedman KD, Abshire TC, DiPaola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, and Montgomery RR: Novel VWF Sequence Variations Identified in Normal Controls and Index Cases Enrolled in the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB-VWD). Blood 2007; 110: 709.

55. Flood VH, Kautza BC, Miller CA, Branchford BR, Gill JC, Haberichter SL, Morateck PA, Christopherson PA, Perry CL , Friedman KD, Bellissimo DB, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Lillicrap D, Goodeve AC, Peak IR, and Montgomery RR: Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing. Blood 2007; 110: 714.

56. Bandarenko N, Park YA, Friedman KD: Unexpected decline in platelet count with TPE therapy for TTP is associated with the strengthening of inhibitor to ADAMTS13. Am J Clin Apheresis. 2008.

57. Dumont LJ, Herschel L, Dumont D, Baker S, Waetrs S, Friedman KD, Graminske S, Dora R, Heldke S, Brooks S, Foster S, Felt T, McAteer M: In Vivo 24 hour recovery of radiolabeled 42-day RBC prepared using the Atreus System. Transfusion 2008;48 (suppl): 37A.

58. McAteer M, Felt T, Friedman K, Vassallo R, Cancelas J, Graminske S, Whitley P, Dumont L, Foster S, ugg N, Herschel L: Analysis of hemolysis failures with donor-specific factors in red blood cell units stored for 42 days. Transfusion 2008;48 (suppl) 176A.

59. Graminske S, Ross D, Heldke S, Friedman KD, Whilley P, Sawyer S, Curartas I, Vassallo R, Foster S, Felt T, McAteer M: Automated separation of whole blood units using the Atreus system: An in-vitro evaluation of non-leukoreduced red blood cell and plasma products. Transfusion 2008;48 (suppl):167.

60. Sawyer S, Whitley P, Cuartas I, Wellingtom M, Vassallo RR, Beddard R, Rugg N, Friedman KD, Graminske S, McAteer M, Foster S, Felt T: In-Vitro evaluation of RBC units obtained after automated separation of whole blood by the Atreus system, leukoreduced, and stored for 42 days. Transfusion 2008;48 (suppl): 170A.

61. Gill JC, Christopherson PA, Flood VH, Friedman KD, Montgomery RR: The Zimmerman Program Investigators: Bleeding Scores in Von Willebrand Disease (VWD) Re-Visited: Analysis of the TS Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 2008;112:425A.

62. Flood VH, Morateck PA, Christopherson PA, Friedman KD, Gill JC, Montgomery RR: The Zimmerman Program Investigators: Unique ELISA-Based Assays for VWF-GPIb Interactions and the Impact of Racial Differences on VWF Testing. Blood 2008; 112: 423A.

63. Jacobi PM, Gill JC, Friedman KD, Montgomery RR, Haberichter SL: Intersection of Mechanisms of Type 2A Von Willebrand Disease through Defects in Von Willebrand Factor Multimerization, Secretion, ADAMTS-13 Susceptibility, and Regulated Storage. Blood 2008; 112: 588A.

64. Jacobi PM, Gill JC, Friedman KD, Montgomery RR, Haberichter SL. Homozygous and heterozygous expression of type 2a von Willebrand disease (VWD) variants: negative impact on mechanisms critical for von willebrand factor (VWF) processing and secretion. J Thromb Haemostas 2009; 7 (supp 2): Abstract AS-WE-038.

65. Cancelos J, Rugg N, Friedman KD, Graminski S, Snyder EL, Corda T, Vassallo RR, Whitley PH, Fender L, Razxatos A. RBCs collected on Trima Accel with press-through RBC leukoreduction and addition of metered RBC storage solution maintain in-vitro quality and in-vivo recovery. Transfusion 2009;49:39A

66. Flood VH, Morateck PA, Christopherson PA, Gill JC, Friedman KD, Montgomery RR. Functional assays for the discrimination of type 2 VWD variants. J Throm Haemostas 2009;7 (supp 2): Abstract OC-TU-071.

67. Flood VH, Lederman C, Wren JS, Christopherson PA, Lee A, Friedman KD, Montgomery RR: A novel VWF A3 domain mutation with absent binding to type I and type III collagen. Blood 2009: 114:228a.

68. Veronica H Flood, MD1, Sandra L Haberichter, PhD1, Kenneth D Friedman, MD2, Steven R Lentz, MD, PhD3, Joan Cox Gill, MD1 and Robert R Montgomery, MD4. VWF binding to types I, III or VI collagen in the ZPMCB-VWD with identification of subjects with selective reduced plasma VWF:CB. Blood 2010; 116, Abstract 235.

69. Friedman KD, Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Montgomery RR, Haberichter SL, Primary Clinical Site Directors. Fourteen Percent of Healthy African Americans participating in the Zimmerman Program for the Molecular and Clinical Biology of VWD are heterozygous for the VWF gene mutation H817Q associated with type 2N von Willebrand Disease. Blood 2010: 116, Abstract 239.

70. Flood VH, Wren JS, Haberichter SL, Friedman KD, Bellissimo DB, Gill JC, Hoffmann RG, Scott JP, Montgomery RR. Low VWF:RCo In Subjects with VWF Polymorphisms D1472H and P1467S Due to Decreased Binding of Ristocetin to the VWF A1 Domain Blood 2010; 116: Abstract 2208.

71. Annen KM, Straus TD, Friedman KD, Kroft SH, Horowitz M, Altmann CL, Gottschall JL, Eshoa C. Two cases of transfusion-transmitted Anaplsma phagocytophilium. Transfusion 2010; 50 (suppl): 200a-201a.

72. Razatos A, Wittevrongel L, Fender L, Cancelas JA, Rugg N, Friedman KD, Graminski S, Vassallo RR, Whitley PH. Apheresis platelets stored in a new platelet additive solution for 5 days are comparable to plasma stored platelets in vitro. Transfusion 2010; 50 (suppl): 43a-44a.

73. Habericther, S.L., Schroeder, J.A., Jacobi, P.M., Gehrand, A.M., Friedman, K.D., DiMichele, D., Montgomery, R.R: A L1278P Von Willebrand Factor (VWF) Mutation Identified In a Type 1 VWD Patient Causes Reduced VWF Secretion And Increased VWF Clearance. J Thromb Haemostas 2011; 9 Suppl 2S:55.

74. Veronica H. Flood, Sandra L. Haberichter, Kenneth D. Friedman, Steven R. Lentz, Joan Cox Gill, and Robert R. Montgomery: Utility of von Willebrand Factor Collagen Binding Assays (VWF:CB) with Type VI Collagen in Diagnosis of VWD. J Thromb Haemostas 2011; 9 Suppl 2S; 201.

75. Punzalan R, Gill JC, Montgomery RR, Haberichter SL, Friedman KD. Reference interval for factor VIII to von Willebrand factor antigen is lower for infants under 6 months of age compared to older children and adults. J Thromb Haemostas 2011;9 suppl 2S; 208.

76. Razatos A, Wittevrongel L, Fender L, Cancelos JA, Rugg N, Friedman KD, Graminske S, Beddard R, Dahman T, McPeck M, Ambruso D. Validation of the Trima Accel System for production of platelet products for storage with platelet additive solution. Transfusion. 2011.

77. Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Montgomery RR. Von Willebrand factor collagen binding provides a sensitive screen for identification of type 2A and 2B von Willebrand disease. Blood 2011; 118:175a.

78. Haberichter SL, Jacobi PM, Flood VH, Christopherson PA, Gill JC, Bellissimo DB, Friedman KD. Quantitative analysis of VWF multimer structure: Discrimination between VWD subtypes. Blood 2011; 118:546a.

79. Petkova J, Bellissimo DM, Halvorson C, Friedman KD. Exon 28 sequencing in von Willebrand disease evaluation- a retrospective review of testing performed at a hemostasis reference laboratory. Awarded the Paul E. Strandjord Young Investigator Award from the Academy of Clinical Physicians and Scientists for 2012.

80. Friedman KD, Jacobi PM, Shaw ME, Endres JL, Haberichter SL. A new chemiluminescent panel for the determination of VWF ristocetin cofactor activity and VWF antigen. Am J Hematolo 2012:87(Suppl 1);S163

81. Crawford JA, Dietrich JE, Hui S-KR, Friedman KD, Mahoney D, Venkateswaran L. Patients with bleeding phenotype and von Willebrand exon 28 polymorphism D1472H: A retrospective analysis at a single institution. Blood 2012; 120:100

82. Haberichter SL, Jacobi PM, Endres JL, Covill SC, Flood VH, Montgomery RR, Gill JC, Friedman KD. Discrimination between VWD subtypes by quantitative analysis of VWF multimer structure. Am J Hematolo 2012:87(Suppl 1);S163.

83. Haberichter SL, Shaw ME, Jacobi PM, Endres JL, Friedman KD. A fully automated platelet-free ristocetin cofactor activity assay for VWD patient evaluation. Am J Hematol 2012:87(Suppl 1);S164.

84. Montgomery RR, Christopherson P, Bellissimo DB, Gill JC, Haberichter SL, Flood VH, Lillicrap D, Goodeve AC, Friedman KD, Abshire TC, Shapiro AD, Ragni MV, Lentz SR, Leissinger CA, Dunn AL, Lusher J, Brown D. The complete Type 1 VWD cohort of the Zimmerman Program for the molecular biology and clinical biology of VWD – Phenotypic assignment, mutation frequency, and bleeding assessment. Submitted to Blood 2013.

85. Haberichter SL, Christopherson PA, Flood VH, Gill JC, Bellissimo DM, Friedman KD, Montgomery RR, Zimmerman Program investigators. Increased Plasma VWF clearance and reduced von Willebrand factor (VWF) synthesis: Distinguishing two mechanisms of moderate to severe type 1 von Willebrand disease (VWD). Submitted to Blood 2013.

86. Flood, VH, Gill JC, Haberichter, SL, Bellissimo DB, Christopherson PA, Friedman KD, Montgomery RR, Zimmerman Program Investigators. Binding of VWF to type, IV collagen: An additional collagen binding mechanism beyond types I, III and VI?. Blood 2013; 122:333

87. Christopherson PA, Flood VH, Cox JC, Bellissimo DB, Friedman KD, Montgomery RR, Zimmerman Investigators. Critical importance of VWF propeptided (VWFpp) in the diagnosis of type 1 von Willebrand disease (VWD). Blood 2013; 122:133

88. Christopherson PA, Bellissimo DB, Cox JC, Haberichter SL, Flood VH, Lillicrap D, Goodeve AC, Friedman KD, Abshire TC, Shapiro AD, Ragni MV, Lentz SR, Leissinger CA, Dunn AL, Lusher J, Brown D. The complete type I cohort of the Zimmerman Program for the Molecular and Clinical Biology of VWD – Phenotypic assignment, mutation frequency, and bleeding assessment. Blood 2013; 112:332

89. Muia J, Zhu J, Haberichter SL, Friedman KD, Feys HB, Vanhoorelbeke K, Gupta G, Westfield LA, Tolia NH, Sadler JE. Allosteric activation of ADAMTS13 involves conformational changes induced by its substrate von Willebrand factor . J Thromb Haemostas 2014; SSC14-1043.

90. Christopherson PA, Gill JC, Flood VL, Friedman KD, Haberichter SL, Montgomery RR. Improved diagnosis of VWD in affected family members using the ISTH bleeding score J Thromb Haemostas 2014; SSC 14-1256.

91. Flood VL, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Montgomery RR, Zimmerman Program for the Molecular and Clinical Biology of VWD. Update on bleeding scores in the Zimmerman Program: Comparison of the ISTH BAT, PBQ and MCMDM-1VWD scoring systems. J Thromb Haemostas 2014; SSC 14-1233.

92. Flood VH, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Udani RA, Montgomery RR, and The Zimmerman Program Investigators. The Management of Bleeding Risk in Von Willebrand Disease: Should Blood Group O Make a Difference? Submitted to Blood 2014.

93. Christopherson PA, Flood VH, Friedman KD, Gill JC, Haberichter SL, Montgomery RR, Abshire TC and the Zimmerman Program Investigators. Impact of Age and Gender on Bleeding Score in Type 1 VWD Using the ISTH-BAT. Blood 2014; 124:1510.

94. Christopherson PA, Bellissimo DB, Gill JC, Haberichter SL, Friedman KD, Udani RA, Roberts JC, Montgomery RR, MD and The Zimmerman Program Investigators. Spectrum of Type 2 Von Willebrand Disease in the Zimmerman Program Blood 2014;124:472.

95. Bellissimo, DB, Udani RA, Christopherson PA, Friedman KD, Gill JC, Haberichter SL, Montgomery RR, Flood VH. Phenotypic variability in carriers of von Willebrand Factor truncating sequence variants in the Zimmerman Program. Blood 2014: 124:2833.

96. Haley KM, Friedman KD, Recht M. A Retrospective Analysis of Bleeding Phenotype and Von Willebrand Factor Exon 28 Polymorphism D1472H at a Single Institution. Blood 2014; 124:2849.

97. Annen K, Reddy A, Berkovitz RS, Friedman KD. Seasonal variation of thrombotic thrombocytopenic purpura across US Climates. Transfusion 2014: 54:184A.

98. Jacobi PM, Covill S, Podd AS, Friedman KD, Haberichter SL. Development and validation of a chromogenic direct thrombin inhibitor (DTI) assay on the ACL TOP 700 for quantifying dabigatran levels. Blood 2014; 124:1548.

99. Gill JC, Flood VH, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Udani RA, Montgomery RR. The management of bleeding risk in von Willebrand disease: Should blood group O make a difference. Blood 2014; 124:2829.

100. Haberichter SL, Jacobi PM, Covill S, Friedman KD. A Chromogenic Direct Thrombin Inhibitor Assay for Quantifying Dabigatran Levels: Development and Validation on the ACL TOP 700. Haemophilia 2015 (may)

101. Friedman KD, Jacobi PM, Covill S, Haberichter SL. Development and Validation of a Chromogenic Factor Xa Inhibitor Assay on the ACL TOP 700 for Quantifying Rivaroxaban Levels. Haemophilia 2015 (May)

102. Kitchen S, Blakemore J, Friedman K, Hart D, Ko RH, Perry D, Platton S, Young G, Luddington RJ. A model to assess costs associated with the use of FVIII and FIX one-stage and chromogenic assays. Presented at International Society for Laboratory Hematology 2015. Abstract 232.

103. Christopherson PA, Bellissimo DB, Flood VH, Friedman KD, Gill JC. Montgomery RR, Haberichter SL. No difference in VWF levels nor VWF survival in index cases and family members with and without p.Y1584C enrolled in the Zimmerman Programs for the molecular and clinical biology of VWD (ZPMCB-VWD) J Thromb Heamost 2015:13(suppl 2) 127.

104. Friedman KD, Christopherson PA, Gill JC, Flood VH, Haberichter SL, Montgomery, RR. Variability in Von Willebrand Factor antigen (VWF:Ag) levels in prospective studies of the Zimmerman Program for the Molecular and Clinical Biology of Von Willebrand disease (ZPMCB-VWD) Subjects. J Thromb Haemost 2015; 13 (suppl 2): 173.

105. Jacobi PM, Covill S, Friedman KD, Haberichter SL. A Chromogenic Factor Xa Inhibitor Assay for Quantifying Rivaroxaban Levels: Optimization and Validation on the ACL TOP 700, J Thromb Haemost 2015; 13 (suppl 2): 393.

106. Mansouri M, Matsumoto M, Cermakova Z, Friedman KD, George JN, Hrachovinova I, Knobel PN, Kokame K, von Krogh AS, Schneppenheim R, Vesely SK, Fujimura Y, Lammle B, Kremer Hovinga JA. Hereditary TTP- A young patient population with high prevalence of arterial thrombotic events. First results from the hereditary TTP Registry. J Thromb Haemost 2015 13(Suppl 2): 153

107. Narayan S, Udani R, Dugan S, Anderson MW, Friedman KD. Atypical Hemolytic Uremic Syndrome (aHUS) due to a Novel Sequence Variation of Diacylglycerol Kinase Epsilon (DGKE). Accepted for presentation at American Society of Nephrology, Poster TH-PO715, 2015

108. VanSandt A, Friedman KD, Vanderlinden SE, Ness PM, Gottschall J. Hemoglobin-based oxygen carriers: Ability and case study. Transfusion 2015; 55 (suppl 3), 179A.

109. VanSandt A, Puca KE, Irani MS, Friedman KD. Successful plasmapheresis for recurrent atypical hemolytic uremic syndrome. Transfusion 2015; 55 Suppl 3, 104A.

110. Haberichter SL, Slobodianuk TL, Podd A, Friedman KD, Flood VH. Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD. Blood 2015; 126:1090.

111. Lake JA, Friedman KD, Flood VH, MD, Jobe SM, Punzalan R, Gill JC. Evaluation of a standardized approach to the diagnosis of mild platelet function defects (MPFD): Recommendation for a targeted approach to diagnosis and identification of a subset of children with a “developmental” form of the disorder. Blood 2015; 126:1052.

112. Christopherson PA, Flood VH,, Haberichter SL, Bellissimo DB, Friedman KD, Gill JC, Udani RA, Montgomery RR, MD the Zimmerman Program Investigators. Domain Distribution of Type 1 VWD Sequence Variants and Impact on Clinical and Laboratory Phenotype in the Zimmerman Program. Blood 2015; 126:758.

113. Trapp-Stamborski V, Dugan SN, Friedman KD, Anderson MW, Udani R. Genetic Evaluation in aHUS: Characterization of a variant of unknown significance in CFHR3. Blood 2015; 126:1053.

114. Alabek ML, Ghate SM, Udani R, Friedman KD, Anderson MW, Malec LM, Palmer LC, Ragni MV, Dugan SN. Complexities and resolution of gene variant interpretation in two hemophilia cases. Presented at World Hemophilia Federation Meeting, Orlando FL, 7/2016

115. Haberichter SL, Christopherson PA, Flood VH, Gill JC, Friedman KD, Montgomery RR, and the Zimmerman Program Investigators. Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels identify the contribution of decreased synthesis and/or increased clearance mechanisms in the pathogenesis of Type 1 von Willebrand Disease (VWD) in the Zimmerman Program. Submitted to American Society of Hematology, 8/2016.

116. Pirelli KJ, Czajkowski CD, Mladenova V, Dugan S, Trapp-Stamborski V, Friedman KD, Udani RA. Laboratory-developed MLPA® probes enable CNV detection in the CFHR4 gene to aid aHUS genetic evaluation [abstract]. Blood 2016; 128, Abstract 1361.

117. Christopherson PA, Udani R, Perry C, Bellissimo DB, Haberichter SL, Flood VH, Friedman KD, Gill JC, Montgomery RR and the Zimmerman Program Investigators. Identification of Copy Number Variants in type 1 and type 3 VWD by aCGH in the Zimmerman Program. [abstract]. Blood 2016; 128, Abstract 872.

118. Padmanabhan, A, Jefcik S, Friedman K. Impact of a data-driven prediction algorithm for blood volume processing in the peripheral blood stem cell collection in unrelated (NMDP) HPC donors. Submitted 12/12/2016 to American Society for Apheresis (Control ID 2692733.)

119. Dugan SN, Friedman KD, McCreery J, Udani R. Maximizing diagnostic certainty for at-risk hemophilia carriers through active test utilization guidance. Submitted to Pediatric Laboratory Utilization Guidance Services (PLUGS) Summit 2017.

120. Dugan SN, Anderson MW, Friedman KD, Czajkowski C, Rauscher D, Birmingham K, Mladenova V, Udani R. The benefit of genetic test utilization guidance in the esoteric hematology reference laboratory. Submitted to Pediatric Laboratory Utilization Guidance Services (PLUGS) Summit 2017.

121. Bercovitz RS, Drew CS, Anani WQ, Friedman KD. A microfluidic analysis of thrombin formation in whole blood samples treated with spray-dried plasma versus fresh frozen plasma. Transfusion 2017; 57 (Suppl 3): 31A.

122. Kremer Hovinga J, Cermakova Z, Fujimura Y, Friedman K, George J, Hrachvinova I, Knobl P, von Krogh AS, Lammle B, Matsumoto M, Schneppenheim R. Hereditary thrombotic thrombocytopenic purpura – Incidence of acute events under plasma prophylaxis. Res Pract Throm Haemost 2017; 57 (suppl 1): 262.

123. Tehseen S, Punzalan R, Udani R, Friedman KD. Atypical hemolytic uremic syndrome: Is complement pathway mutation analysis over-utilized? Experience of a large reference laboratory. Transfusion 2017; 57 (Suppl 3) 129A.

124. Haberichter SL, Christopherson PA, Flood VH, Gill JC, Friedman KD, Montgomery RR, and the Zimmerman Program Investigators. Quantitative Analysis of Von Willebrand Factor (VWF) Multimers in Von Willebrand Disease (VWD) Patients Recruited through the Zimmerman Program for the Molecular and Clinical Molecular Biology of VWD. Submitted to Blood 2017.

125. Rashid A, Friedman KD, Mushtaq N. Identification of a novel mutation in a patient with congenital thrombotic thrombocytopenic purpura. Res and Pract Thromb Haemost 2018; 2 (Suppl 1) xxx.

126. Wang L, Sullivan M, Dugan S, Trapp-Stamborski V, McCreery J, Springer M, Rauscher D, Tracy S, D.P. Dash, Friedman K, and Perez-Botero J. Definitive diagnosis of gray platelet syndrome (GPS) established by identification of novel NBEAL2 pathogenic variants highlights the utility of next-generation sequencing (NGS) for diagnosing rare platelet disorders. The ACMG Annual Clinical Genetics Meeting, Seattle, WA 2019.

127. Malec L, Sharma R, Perez-Botero J, Agostini TA, Podd AS, Haberichter SL, Friedman KD. Performance of VWF:GPIbM assay for monitoring of desmopressin (DDAVP) trials/ Submitted to HTRS meeting, 2019

128. Puca K, Restivo J, Anani W, Friedman KD. Extended storage of thawed cryoprecipitate at 20-240C and 1-6oC has limited effect on fibrinogen concentration. Submitted to AABB 2019.

129. van Dorland AH, Mansouri Taleghani M, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I2, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, VeselySK, Matsumoto M, Lämmle B, Fujimura Y, and Kremer Hovinga JA; Hereditary TTP Registry. Prevalence of arterial thrombotic events in an international cohort of 123 patients with hereditary thrombotic thrombocytopenic purpura. Submitted to Swiss Oncology and Hematology Conference, April 2019.

130. Dugan SN, Miller AC, Sullivan MJ, Trapp-Stamborski V, Sharma R, Friedman KD, BR, McCreeryJ, and Perez Botero J. MYH9 Diagnostic Yield: Reported Phenotypic Specificity Highlights Opportunity for Increased Clinician-Laboratory Partnership. Submitted to National Society of Genetics Counselors, 2019.

131. Escobar M, Montanez N, Scully M, Hellerstedt B, Dugan S, Friedman K. Non-severe Congenital deficiency of ADAMTS13 presenting as thrombotic microangiopathy during pregnancy. Presented at ISTH 2019.

132. Malec LM, Croteau SE, Callaghan M, Matino D, Friedman KD, Sidonio RF. Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of selected US and Canadian Hemophilia Treatment Centers. Submitted to ASH, 2019.

133. Springer MG, Perez-Botero J, Dugan SN, McCreery J, Sharma R, Trapp-Stamborski V, Sullivan MJ, Tracey S, Friedman KD. Low prevalence of pathogenic or likely pathogenic variants in a USA cohort evaluated for genetic causes of atypical hemolytic uremic syndrome, (aHUS). Presented at Canadian Complement Conference, March 2020.

134. Weyland AC, Friedman KD, Gupta S, Haley K, He C, Pels SG, Roberts JC, Watson C, Sidonio RF. Bleeding in patients with clinically severe von Willebrand disease: Preliminary results of ATHN 9, a natural history study of the safety, efficacy , effectiveness and practice of treatment for people with severe von Willebrand disease. Submitted to Blood 2020.

135. Thornberg CD, He C, Malec L, van den Berg M, Friedman KD, Watson C, Carpenter SL. US cohort study of previously untreated patients with congenital hemophilia (ATHN 8: Pups Study): Association between family history and bleeding within the first 30 days of life. Accepted to Blood 2020.

136. Kozak M, Rubenstein W, Okwan D, Nassir Y, Friedman K, Gibb D, Klapper E, Pepkowitz, S. Durable remission of immune thrombotic thrombocytopenic purpura in the setting of recent Pembrolizumab therapy. Submitted to ASFA 2021.

137. Weyland AC, Fedor C, Friedman KD, Gupta S, Haley KM, He C, Hirsh N, Pels SG, Roberts JC, Tung TT, Sidonio RF. Bleeding in patients with clinically severe von Willebrand disease: Interim analysis of ATHN 9, A natural history study of people with severe von Willebrand disease (VWD). Blood 2021.

138. Borogovac, A, Tarasco E, Kremer Hovinga J, Friedman KD, Asch A, Vesely SK, Prodan C, George JN. Prevalence of stroke and cognitive impairment in patients with hereditary Thrombotic Thrombocytopenic Purpura. Blood 2021;.

139. Lee, K, Ross JE, Christopherson P, Corrales I, Desch K, Eikenboom J, Friedman K, Futch I, Hankey W, Springer M, Hampshire D, Johnson J, Lillicrap D on behalf of the ClinGen von Willebrand Disease Variant Curation Expert Panel. Optimization variant curation guidelines to improve clinical genetic testing and diagnosis of von Willebrand Disease. ISTH, 2022.

140. Tarasco E, Friedman KD, George JN, Knobl P, Hrachovinova I, Matsumoto M, Schneppenheim R, Von Krogh AS, Lammle B, Kremmer Hovinga Strebel JA.l. Neonatal exchange transfusion: when should we think about hereditary thrombotic thrombocytopenic purpura (hTTP)? Abstract #137. Presented at the 2022 American Society of Hematology Annual Meeting and Exposition; December 10, 2022; New Orleans, Louisiana.

141. Faye L, Christopherson PA, Haberichter SL, Friedman KD, Montgomery RR, Flood VH. Type 2M VWD laboratory defects more consistent that bleeding symptoms across family members. Abstract 3785--. Presented at the 2022 American Society of Hematology Annual Meeting and Exposition; December 10, 2022; New Orleans, Louisiana.

142. Bajguz, DA, Trapp-Stamborski V, Palmer EL, Smith CC, Czajkowski CD, Meyers SJ, Miller AP, Sugan SN, Friedman KD, Perez Botero J. When is factor VIII deficiency not hemophilia A? Variant F8 c.1094 A>G, p.tyr365Cys illustrates the utility of genotyping and the value of disease specific expertise in variant classification. Submitted to ISTH 2023.

143. Tarasco E, Stalder O, Friedman KD, George JN, Knöbl PN, Hrachovinova I, Matsumoto M, Schneppenheim R, von Krogh AS, Lämmle B, Kremer Hovinga JA, Transient ischemic attacks (TIAs) and ischemic strokes are leading events in hereditary thrombotic thrombocytopenic purpura (hTTP). Submitted to ISTH 2023.

144. Flowers A, Friedman KD, et. Analysis of Donors deferred for vCJD risks and impact of revised FDA guidance. Submitted to AABB 2023

145. Schraner M, Tarasco E, Stalder O, Friedman, KD, George JN, Hrachovinova I, Knöbl PN, Matsumoto M, Schneppenheim R, Von Krogh A-S, Cermakova Z, Górska-Kosicka M, Sakai K, Sinkovits G, El Chazli Y, Largiadèr CR, Pikovsky O, WindygaJ , Lämmle B, Kremer Hovinga JA. Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry. Blood 2023

146. (Unrefereed) Smith KJ, Friedman KD, Hodges F, Wiltbank T. Recovery of coagulation factors after 30 nm micro porous membrane filtration of plasma or cryoprecipitate. Presented at the American Society of Hematology. Blood 1991;78:352a.

147. (Unrefereed) Friedman KD, Saddler MC, Tarnower AC, Yang G, Harford AM. Transient renal failure in a patient with idiopathic thrombocytopenic purpura after treatment with con¬comitant protein A immunosorption and intravenous immune globulin. Presented at the American Society of Hematology. Blood 1992;80:483a.

148. (Unrefereed) Hessner MJ, Luhm RA, Endres-Brooks JL, Han K, Friedman KD, Montgomery RR: Allelic frequencies of prothrombin G20210A, Factor V G1691A (Leiden), and 5,10 methylene tetrahydrofolate reductase (MTHFR) C677T determined by triplex allele-specific PCR in seven different populations. Blood 1997; 90:116b.

149. (Unrefereed) Divgi A, Thumma S, Hari P, Friedman KD. Delayed-onset heparin-induced thrombocytopenia (HIT) presenting after undocumented drug exposure as post-angiography pulmonary embolism. Blood 2003;102:127b.

1. Post transfusion graft vs. host disease and irradiation of blood components. Transfusion Medicine Audio Digest. February 1995.

2. The Hypercoaguable State: New Developments in Thrombosis and Anticoagulation. Update and Review of Internal Medicine. Arora S, Chopra S, Abrahamson MJ, editors. CME Information Services, Teterboro, NJ, 1999.

3. The TIMI Study Group: The thrombolysis in myocardial infarction trial: Phase I findings. N Engl J Med 1985;312:932 936.

4. Hillis LD, Borer J, Braunwald E, et al: High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multi center trial. J American College of Cardiology 1985;6:957 962.

5. Price TH, Goodnough LT, Vogler WR, et al. The effect of recombinant erythro-poietin on the efficacy of autologous blood donation in patients with anemia: A multi center randomized double blinded controlled trial. Transfusion 1996;36:29 36.

6. Gottschall JL, ed., Friedman KD, King K, Nguyen K-A, Pomper G, Sesok-Pizzini D, Wu Y, contrib eds. Blood Transfusion Therapy – A Physician’s Handbook. 8th Edition, Bethesda: American Association of Blood Banks Banks, Bethesda, 2005.

7. JH Waters, D Cheng, A. Shandler, DF Szpisjak, JL Gottschall eds. (Kenneth D. Friedman listed as a contributor.) Perioperative Blood Management – A Physician’s Handbook. Bethesda: American Association of Blood Banks Banks, Bethesda, In Press for 2006.

8. King KE, ed., N Bandarenko, Campbell-Lee SA, Cooling LW, Cushing MM, Friedman KD, Pomper G, Blood Transfusion Therapy – A Physician’s Handbook. 9th Edition, Bethesda: American Association of Blood Banks Banks, Bethesda, 2008.

9. King KE, ed., N Bandarenko, Campbell-Lee SA, Cooling LW, Cushing MM, Friedman KD, Pomper G. Blood Transfusion Therapy – A Physician’s Handbook. 10th Edition, Bethesda: AABB, Bethesda, 2011.

10. N Bandarenko N, ed., Campbell-Lee SA, Cooling LW, Cushing MM, Delaney M, Friedman KD, Pomper G, Raval JS. Blood Transfusion Therapy – A Physician’s Handbook. 11th Edition, Bethesda: AABB, Bethesda, 2014.

11. N Bandarenko N, ed., Campbell-Lee SA, Cooling LW, Cushing MM, Delaney M, Friedman KD, Poisson, JL, Raval JS, Yazer MH. Blood Transfusion Therapy – A Physician’s Handbook. 12th Edition, Bethesda: AABB, Bethesda, 2017.

12. Scully M, Cataland SR, Peyvandi F, Coppo P, Knoble P, Kremer Hovinga JA, Matjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK, HERCULES Investigators. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380:335-346.

13. Cushing MM. Poisson JL, ed., Annen KM, Campbell-Lee SA, Cooling LW, Cushing MM, Friedman KD, McGuinn CE, Punzalan RC, JL, Raval JS, Yazer MH. Blood Transfusion Therapy – A Physician’s Handbook. 13th Edition, Bethesda: AABB, Bethesda, 2020.